CAM
FLGT icon

Cormorant Asset Management’s Fulgent Genetics FLGT Stock Holding History

Cormorant Asset Management’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-750,000
Closed -$4.79M – 58
2017
Q2 		$4.79M Hold
750,000
– – 0.79% 35
2017
Q1 		$8.19M Sell
750,000
-107,663
-13% -$1.27M 1.19% 30
2016
Q4 		$9.92M Buy
857,663
+57,663
+7% +$544K 1.34% 24
2016
Q3 		$7.38M Buy
+800,000
New +$7.36M 0.81% 41

Other funds holding FLGT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
SC
Scholtz & Company Stamford, Connecticut $195M AUM 12.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cormorant Asset Management's FLGT Position: Q3 2017 in Review

Cormorant Asset Management sold out of Fulgent Genetics (FLGT) in Q3 2017, closing a stake of 750,000 shares — an estimated $4.79M sold.

Cormorant Asset Management first reported a position in FLGT in Q3 2016 and held it in 4 quarters. The position peaked at $9.92M in Q4 2016. 21 funds tracked by Wall St. Rank hold FLGT as of Q3 2017.

  • Cormorant Asset Management reported no remaining Fulgent Genetics position as of Q3 2017 after selling out during the quarter.
  • Cormorant Asset Management sold 750,000 Fulgent Genetics shares in Q3 2017, an estimated $4.79M.
  • Cormorant Asset Management first reported a position in Fulgent Genetics in Q3 2016 and held it in 4 quarters.
  • Cormorant Asset Management's Fulgent Genetics position peaked at $9.92M in Q4 2016.
  • 21 funds tracked by Wall St. Rank held Fulgent Genetics as of Q3 2017.

Based on Cormorant Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.